Benefits and Pitfalls of a Glycosylation Inhibitor Tunicamycin in the Therapeutic Implication of Cancers
S Banerjee, AA Ansari, SP Upadhyay, DJ Mettman… - Cells, 2024 - mdpi.com
The aberrant glycosylation is a hallmark of cancer progression and chemoresistance. It is
also an immune therapeutic target for various cancers. Tunicamycin (TM) is one of the potent …
also an immune therapeutic target for various cancers. Tunicamycin (TM) is one of the potent …